The recent validation from the June 30, 2026, Chairman’s Update confirms that the strategic distribution partnership with Electrome Corporation has officially moved forward, satisfying initial conditions and executing the first purchase orders.
Combined with the company reporting a "small profit for calendar year 2025," aggressive cost reduction (office relocation and staff downsizing), and a $41M tax-loss carryforward, the financial pathway to the PPS milestones is highly compressed.
Timeline for how BIEL could scale to meet these profit milestones based on the Electrome commercial rollout.
The BIEL / Electrome Milestone Timeline
Phase 1: The Magic Number ($250K Profit) ➔ $0.01 PPS
Target Window: Q3 – Q4 2026
Catalyst: Electrome’s official commercial launch and fulfillment of initial purchase orders.
Investor Psychology: As noted, investors will price this in before the 10-K or 10-Q reports. When Electrome provides public metrics or press releases regarding early consumer adoption and platform integration, speculative volume will flood the ~24.7B shares outstanding.
The Math: Achieving $250K in profit requires very minimal revenue overhead now that BIEL is a lean, 4-employee operation with strict cost controls. A P/E of 1,000 on $250K net income supports a market cap of $250M, lifting the current fraction-of-a-cent price ($0.0003) straight into "copper" ($0.01).
Phase 2: Scaling Up ($1M Profit) ➔ $0.04 PPS
Target Window: H1 2027
Catalyst: Consistent, re-occurring purchase orders from Electrome alongside existing channels (Taiwan, veterinary, etc.).
The Acceleration: The $41M tax-loss carryforward acts as a shield, ensuring that every dollar of operational revenue over expenses goes straight to the bottom line without federal tax erosion. Reaching $1M in profit requires roughly $2M–$2.5M in gross revenue, which is well within reach as Electrome scales manufacturing.
Phase 3: The Inflection Point ($2M Profit) ➔ $0.08 PPS
Target Window: Late 2027
Catalyst: Expanded clinical adoption of Pulsed Shortwave Therapy (PSWT) in surgical/postoperative settings and international distribution traction.
Market Dynamics: At $2M in pure profit, BIEL transitions from an OTC micro-cap story into a fundamentally sound, high-growth medical device play.
Phase 4: History in the Making ($2.5M Profit) ➔ $0.10 PPS
Target Window: Mid-2028 (Within the "year or two" window)
Catalyst: Total market penetration via Electrome's commercial platform and mature multi-channel revenue.
The Result: A $0.10 PPS translates to a market capitalization of roughly $2.47 Billion. With zero tax liabilities on the horizon due to the carryforward, an explosive margins profile makes this milestone entirely achievable if Electrome can effectively capture a slice of the multi-billion-dollar non-opioid chronic pain market.
Combined with the company reporting a "small profit for calendar year 2025," aggressive cost reduction (office relocation and staff downsizing), and a $41M tax-loss carryforward, the financial pathway to the PPS milestones is highly compressed.
Timeline for how BIEL could scale to meet these profit milestones based on the Electrome commercial rollout.
The BIEL / Electrome Milestone Timeline
Phase 1: The Magic Number ($250K Profit) ➔ $0.01 PPS
Target Window: Q3 – Q4 2026
Catalyst: Electrome’s official commercial launch and fulfillment of initial purchase orders.
Investor Psychology: As noted, investors will price this in before the 10-K or 10-Q reports. When Electrome provides public metrics or press releases regarding early consumer adoption and platform integration, speculative volume will flood the ~24.7B shares outstanding.
The Math: Achieving $250K in profit requires very minimal revenue overhead now that BIEL is a lean, 4-employee operation with strict cost controls. A P/E of 1,000 on $250K net income supports a market cap of $250M, lifting the current fraction-of-a-cent price ($0.0003) straight into "copper" ($0.01).
Phase 2: Scaling Up ($1M Profit) ➔ $0.04 PPS
Target Window: H1 2027
Catalyst: Consistent, re-occurring purchase orders from Electrome alongside existing channels (Taiwan, veterinary, etc.).
The Acceleration: The $41M tax-loss carryforward acts as a shield, ensuring that every dollar of operational revenue over expenses goes straight to the bottom line without federal tax erosion. Reaching $1M in profit requires roughly $2M–$2.5M in gross revenue, which is well within reach as Electrome scales manufacturing.
Phase 3: The Inflection Point ($2M Profit) ➔ $0.08 PPS
Target Window: Late 2027
Catalyst: Expanded clinical adoption of Pulsed Shortwave Therapy (PSWT) in surgical/postoperative settings and international distribution traction.
Market Dynamics: At $2M in pure profit, BIEL transitions from an OTC micro-cap story into a fundamentally sound, high-growth medical device play.
Phase 4: History in the Making ($2.5M Profit) ➔ $0.10 PPS
Target Window: Mid-2028 (Within the "year or two" window)
Catalyst: Total market penetration via Electrome's commercial platform and mature multi-channel revenue.
The Result: A $0.10 PPS translates to a market capitalization of roughly $2.47 Billion. With zero tax liabilities on the horizon due to the carryforward, an explosive margins profile makes this milestone entirely achievable if Electrome can effectively capture a slice of the multi-billion-dollar non-opioid chronic pain market.
1
